NVO
Income statement / Annual
Last year (2024), Novo Nordisk A/S's total revenue was $290.40 B,
an increase of 25.03% from the previous year.
In 2024, Novo Nordisk A/S's net income was $100.99 B.
See Novo Nordisk A/S,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$290.40 B |
$232.26 B |
$176.95 B |
$140.80 B |
$126.95 B |
$122.02 B |
$111.83 B |
$111.70 B |
$111.78 B |
$107.93 B |
| Cost of Revenue |
$44.52 B
|
$35.77 B
|
$28.45 B
|
$23.66 B
|
$20.93 B
|
$20.09 B
|
$17.62 B
|
$17.63 B
|
$17.18 B
|
$16.19 B
|
| Gross Profit |
$245.88 B
|
$196.50 B
|
$148.51 B
|
$117.14 B
|
$106.01 B
|
$101.93 B
|
$94.21 B
|
$94.06 B
|
$94.60 B
|
$91.74 B
|
| Gross Profit Ratio |
0.85
|
0.85
|
0.84
|
0.83
|
0.84
|
0.84
|
0.84
|
0.84
|
0.85
|
0.85
|
| Research and Development Expenses |
$48.06 B
|
$32.44 B
|
$24.05 B
|
$17.77 B
|
$15.46 B
|
$14.22 B
|
$14.81 B
|
$14.01 B
|
$14.56 B
|
$13.61 B
|
| General & Administrative Expenses |
$5.28 B
|
$4.86 B
|
$4.47 B
|
$4.05 B
|
$3.96 B
|
$4.01 B
|
$3.92 B
|
$3.78 B
|
$3.96 B
|
$3.86 B
|
| Selling & Marketing Expenses |
$62.10 B
|
$56.74 B
|
$46.22 B
|
$37.01 B
|
$32.93 B
|
$31.82 B
|
$29.40 B
|
$28.34 B
|
$28.38 B
|
$28.31 B
|
| Selling, General & Administrative Expenses |
$67.38 B
|
$61.60 B
|
$50.68 B
|
$41.06 B
|
$36.89 B
|
$35.83 B
|
$33.31 B
|
$32.12 B
|
$32.34 B
|
$32.17 B
|
| Other Expenses |
$2.10 B
|
-$119.00 M
|
-$1.03 B
|
-$332.00 M
|
-$460.00 M
|
-$600.00 M
|
-$1.15 B
|
-$1.04 B
|
-$737.00 M
|
-$3.48 B
|
| Operating Expenses |
$117.54 B
|
$93.92 B
|
$73.70 B
|
$58.50 B
|
$51.89 B
|
$49.45 B
|
$46.97 B
|
$45.10 B
|
$46.17 B
|
$42.30 B
|
| Cost And Expenses |
$162.06 B
|
$129.69 B
|
$102.15 B
|
$82.16 B
|
$72.82 B
|
$69.54 B
|
$64.58 B
|
$62.73 B
|
$63.35 B
|
$58.48 B
|
| Interest Income |
$1.84 B
|
$1.07 B
|
$239.00 M
|
$231.00 M
|
$312.56 M
|
$64.15 M
|
$51.00 M
|
$69.00 M
|
$52.00 M
|
$56.00 M
|
| Interest Expense |
$1.64 B
|
$542.00 M
|
$378.00 M
|
$289.00 M
|
$500.84 M
|
$494.47 M
|
$85.00 M
|
$90.00 M
|
$65.00 M
|
$67.00 M
|
| Depreciation & Amortization |
$8.55 B
|
$9.41 B
|
$7.36 B
|
$6.03 B
|
$5.75 B
|
$5.66 B
|
$3.93 B
|
$3.18 B
|
$3.19 B
|
$2.96 B
|
| EBITDA |
$137.38 B |
$114.63 B |
$76.80 B |
$65.39 B |
$59.27 B |
$54.43 B |
$51.63 B |
$51.95 B |
$51.06 B |
$46.51 B |
| EBITDA Ratio |
0.47
|
0.49
|
0.43
|
0.46
|
0.47
|
0.45
|
0.46
|
0.47
|
0.46
|
0.43
|
| Operating Income Ratio |
0.44
|
0.44
|
0.42
|
0.42
|
0.43
|
0.43
|
0.42
|
0.44
|
0.43
|
0.46
|
| Total Other Income/Expenses Net |
-$1.15 B
|
$2.10 B
|
-$5.75 B
|
$436.00 M
|
-$996.00 M
|
-$3.93 B
|
$367.00 M
|
-$287.00 M
|
-$634.00 M
|
-$5.96 B
|
| Income Before Tax |
$127.19 B
|
$104.67 B
|
$69.06 B
|
$59.08 B
|
$53.13 B
|
$48.55 B
|
$47.62 B
|
$48.68 B
|
$47.80 B
|
$43.48 B
|
| Income Before Tax Ratio |
0.44
|
0.45
|
0.39
|
0.42
|
0.42
|
0.4
|
0.43
|
0.44
|
0.43
|
0.4
|
| Income Tax Expense |
$26.20 B
|
$20.99 B
|
$13.54 B
|
$11.32 B
|
$10.99 B
|
$9.60 B
|
$8.99 B
|
$10.55 B
|
$9.87 B
|
$8.62 B
|
| Net Income |
$100.99 B
|
$83.68 B
|
$55.53 B
|
$47.76 B
|
$42.14 B
|
$38.95 B
|
$38.63 B
|
$38.13 B
|
$37.93 B
|
$34.86 B
|
| Net Income Ratio |
0.35
|
0.36
|
0.31
|
0.34
|
0.33
|
0.32
|
0.35
|
0.34
|
0.34
|
0.32
|
| EPS |
22.67 |
18.67 |
12.26 |
10.4 |
9.03 |
8.21 |
7.98 |
7.71 |
7.5 |
6.78 |
| EPS Diluted |
22.63 |
18.62 |
12.22 |
10.37 |
9.01 |
8.19 |
7.97 |
7.7 |
7.48 |
6.76 |
| Weighted Average Shares Out |
$4.45 B
|
$4.48 B
|
$4.53 B
|
$4.59 B
|
$4.67 B
|
$4.75 B
|
$4.84 B
|
$4.96 B
|
$5.07 B
|
$5.16 B
|
| Weighted Average Shares Out Diluted |
$4.46 B
|
$4.49 B
|
$4.54 B
|
$4.61 B
|
$4.68 B
|
$4.76 B
|
$4.85 B
|
$4.96 B
|
$5.07 B
|
$5.16 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
